BURNABY, BC, Oct. 30 /CNW/ - Welichem Biotech Inc. (the "Company")
(TSX-V: WBI), announced today that the Company filed its first quarter
financials and MD & A. The net loss for the 3-month period ended August 31,
2007 were $593,104 (2006 - $866,701) and 1 cent per share (2006 - 3 cents per
Detailed information is available on SEDAR website (www.sedar.com).
About Welichem Biotech Inc.
Welichem Biotech Inc. is a publicly-traded biotechnology company
developing therapeutic drugs in the fields of autoimmune diseases and cancer.
ON BEHALF OF THE BOARD
York Yingping Guo
President & Chief Executive Officer
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this news
release. This press release contains forward-looking statements that include
our belief as to the potential of our products. Certain risks and
uncertainties such as our ability to successfully commercialize the products
could cause the Company's actual results to differ materially from those in
the forward-looking statements.
For further information:
For further information: York Yingping Guo, Tel.: (604) 432-1703, Email:
email@example.com; Yan Chen, Business Development Manager, Tel.: (604)
432-1703, Email: firstname.lastname@example.org